Stockscreener 앱 받기
12.76
5.55%
-0.75
전일 마감가:
$13.51
열려 있는:
$13.27
하루 거래량:
6.38M
Relative Volume:
0.73
시가총액:
$2.51B
수익:
-
순이익/손실:
$-29.46M
주가수익비율:
-55.89
EPS:
-0.2283
순현금흐름:
$-28.17M
1주 성능:
-14.82%
1개월 성능:
+78.46%
6개월 성능:
+268.79%
1년 성능:
+573.35%
1일 변동 폭
$12.49
$13.36
1주일 범위
$12.00
$15.57
52주 변동 폭
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
12.76 | 2.51B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits
Sellas Life Sciences: REGAL Trial's Delayed Events Signal Selection Bias (SLS) - Seeking Alpha
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Raises Target Price to $30 - Moomoo
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
Here’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026 - Yahoo Finance
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
Why SELLAS Life Sciences Group (SLS) Stock Is Down Today - Moomoo
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail - Stocktwits
SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success - Stocktwits
SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals - StocksToTrade
SLS Stock In The Spotlight As CEO Pushes Back On Regal Trial Criticism – ‘Let’s Separate The Noise From The Data’ - Yahoo Finance
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall - Benzinga
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SLS Stock Logs 2-Day Losing Streak: Mixed Institutional Bets Emerge Ahead Of Key AML Trial Update - TradingView
5 Best Performing American Stocks in June 2026 - Insider Monkey
SLS Stock: SELLAS Investors Look For More After 542% Surge - CMC Markets
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment - Intellectia AI
SELLAS Life Sciences Stock (SLS) Opinions on Phase 3 Trial Speculation - Quiver Quantitative
This Little-Known Stock Has Surged 550% in the Past Year - Yahoo Finance
Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Can Afford To Invest In Growth - Moomoo
SLS Stock Notches 3-Week Winning Run: MassMutual Opens Tiny Stake Ahead Of Key AML Readout - TradingView
SLS Stock In Focus As Alliance Global Sees 92% Upside Following AML Trial Updates - Stocktwits
SLS Should I Buy - Intellectia AI
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):